<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05019625</url>
  </required_header>
  <id_info>
    <org_study_id>2014P001727</org_study_id>
    <nct_id>NCT05019625</nct_id>
  </id_info>
  <brief_title>Biomarker Development for Muscular Dystrophies</brief_title>
  <official_title>Biomarker Development for Muscular Dystrophies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wake Forest University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current methods of measuring the response to new treatments for muscular dystrophies involve&#xD;
      the examination of small pieces of muscle tissue called biopsies. The investigators are&#xD;
      interested in finding less invasive methods that reduce the need for muscle biopsies. The&#xD;
      purpose of this research is to learn about the possibility of detecting and measuring the&#xD;
      activity and severity of muscular dystrophies by examining a urine sample and a blood sample,&#xD;
      and some muscles in the arms and legs using tests called ultrasound and electrical impedance&#xD;
      myography; both tests are painless and non-invasive. The information that is gathered from&#xD;
      this study may help to evaluate, prevent, diagnose, treat, and improve the understanding of&#xD;
      human muscle diseases.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2015</start_date>
  <completion_date type="Anticipated">June 2027</completion_date>
  <primary_completion_date type="Anticipated">June 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Extracellular RNA in biofluids</measure>
    <time_frame>6 years</time_frame>
    <description>The extracellular RNA biomarkers in the muscular dystrophy groups will be evaluated and compared with the extracellular RNA content in control groups. Statistical analysis will be used to evaluate the sensitivity and specificity of these markers as measurements of disease activity and severity based on clinical measurements of muscle power, electrocardiogram parameters, pulmonary function test parameters, muscle tissue composition using quantitative ultrasound and electrical impedance myography, and muscle tissue specimens.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">465</enrollment>
  <condition>Myotonic Dystrophy</condition>
  <condition>Duchenne Muscular Dystrophy</condition>
  <condition>Becker Muscular Dystrophy</condition>
  <condition>Facioscapulohumeral Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Single biofluid collection</arm_group_label>
    <description>We will ask eligible volunteers to provide a single urine sample and undergo a single blood draw.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Serial biofluid and muscle function testing</arm_group_label>
    <description>We will ask eligible volunteers to provide a urine sample, a blood sample, and undergo standard muscle function tests once every six months over a two-year period, and undergo pulmonary function tests and electrocardiogram once per year for two years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biofluid and muscle tissue biopsy</arm_group_label>
    <description>We will ask eligible volunteers to provide a urine sample and undergo a muscle biopsy once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ultrasound and myography testing</arm_group_label>
    <description>We will ask eligible volunteers to provide a single urine sample, a single blood draw, and undergo ultrasound and electrical impedance myography studies once.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      biofluid; muscle tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Males and females ages 5 years and older with myotonic dystrophy type 1 (DM1), myotonic&#xD;
        dystrophy type 2 (DM2), Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD),&#xD;
        and facioscapulohumeral muscular dystrophy (FSHD) confirmed by genetic testing or by&#xD;
        clinical history and examination are invited to participate. In addition, male and female&#xD;
        healthy volunteers ages 18 and older also are invited to participate.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with DM1 or DM2 based on genetic testing and/or clinical criteria (some&#xD;
             subjects who have positive genetic testing may be asymptomatic, while other subjects&#xD;
             who show characteristic clinical features may have declined to have genetic testing&#xD;
             done). Control non-DM subjects are unknown to have DM or any other muscular dystrophy&#xD;
             by history and may have had no genetic testing.&#xD;
&#xD;
          -  Able to provide informed consent or assent for participation in the study.&#xD;
&#xD;
          -  Demographic characteristics for single biofluid collection: Males and females age 5&#xD;
             years and older.&#xD;
&#xD;
          -  Demographic characteristics for serial biofluid and muscle function testing: Males and&#xD;
             females age 14 years and older with DM1.&#xD;
&#xD;
          -  Demographic characteristics for biofluid and muscle biopsy: Males and females, ages&#xD;
             18-65 years.&#xD;
&#xD;
        Demographic characteristics for single biofluid collection, ultrasound, and myography:&#xD;
        Males and females age 14 years and older.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical history of any of the following. State of immunosuppression; coagulopathy;&#xD;
             pre-existing liver or kidney disease; documented HIV positive; documented hepatitis B&#xD;
             and/or C positive.&#xD;
&#xD;
          -  Medications and other drugs. Use of anti-platelet drugs within 7 days prior to blood&#xD;
             draw or biopsy; use of anticoagulants within 60 days prior to blood draw or biopsy;&#xD;
             active drug or alcohol use or dependence that, in the opinion of the biopsy surgeon,&#xD;
             would interfere with post-procedure wound care.&#xD;
&#xD;
          -  Other. Inability or unwillingness of the subject to give written informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thurman M. Wheeler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Parker Conquest</last_name>
    <phone>617-726-7506</phone>
    <email>econquest@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brigham McKee</last_name>
    <phone>617-726-7506</phone>
    <email>bmckee2@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis Beers</last_name>
      <email>lbeers@bwh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Anthony Amato, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parker Conquest</last_name>
      <phone>617-726-7506</phone>
      <email>econquest@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brigham McKee</last_name>
      <phone>617-726-7506</phone>
      <email>bmckee2@mgh.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Thurman M. Wheeler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paloma Gonzalez-Perez, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Constance Linville</last_name>
      <phone>336-716-4568</phone>
      <email>clinvill@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Araya Puwanant, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerry M. Oddis, RN, CCRC</last_name>
      <phone>412-692-4918</phone>
      <email>kmoddis@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Paula R. Clemens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Antoury L, Hu N, Balaj L, Das S, Georghiou S, Darras B, Clark T, Breakefield XO, Wheeler TM. Analysis of extracellular mRNA in human urine reveals splice variant biomarkers of muscular dystrophies. Nat Commun. 2018 Sep 25;9(1):3906. doi: 10.1038/s41467-018-06206-0.</citation>
    <PMID>30254196</PMID>
  </reference>
  <reference>
    <citation>Antoury L, Hu N, Darras B, Wheeler TM. Urine mRNA to identify a novel pseudoexon causing dystrophinopathy. Ann Clin Transl Neurol. 2019 May 17;6(6):1106-1112. doi: 10.1002/acn3.777. eCollection 2019 Jun.</citation>
    <PMID>31211175</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 16, 2021</study_first_submitted>
  <study_first_submitted_qc>August 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Thurman Wheeler, M.D</investigator_full_name>
    <investigator_title>Physician Scientist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
    <mesh_term>Myotonic Dystrophy</mesh_term>
    <mesh_term>Muscular Dystrophy, Facioscapulohumeral</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

